Oric Pharmaceuticals (NASDAQ:ORIC – Get Free Report) is projected to post its Q3 2026 results after the market closes on Thursday, November 12th. Analysts expect Oric Pharmaceuticals to post earnings of ($0.3861) per share for the quarter. Parties can check the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Friday, November 20, 2026 at 4:00 PM ET.
Oric Pharmaceuticals Stock Performance
NASDAQ ORIC opened at $9.23 on Tuesday. The firm’s 50 day moving average price is $11.90 and its 200-day moving average price is $11.08. Oric Pharmaceuticals has a 52-week low of $7.23 and a 52-week high of $14.68. The company has a market cap of $956.69 million, a PE ratio of -6.84 and a beta of 1.23.
Wall Street Analyst Weigh In
A number of equities analysts recently commented on the stock. HC Wainwright boosted their price objective on shares of Oric Pharmaceuticals from $25.00 to $27.00 and gave the stock a “buy” rating in a research note on Monday, August 10th. Wall Street Zen raised Oric Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Saturday, July 25th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Oric Pharmaceuticals in a report on Thursday, October 15th. Leerink Partners assumed coverage on Oric Pharmaceuticals in a report on Monday, October 5th. They issued an “outperform” rating and a $26.00 price target on the stock. Finally, JPMorgan Chase & Co. boosted their price target on Oric Pharmaceuticals from $23.00 to $26.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 14th. Fourteen equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $21.25.
Read Our Latest Stock Analysis on ORIC
Insider Activity at Oric Pharmaceuticals
In other news, CFO Dominic Piscitelli sold 14,000 shares of the firm’s stock in a transaction dated Tuesday, October 20th. The shares were sold at an average price of $13.53, for a total value of $189,420.00. Following the sale, the chief financial officer directly owned 69,828 shares in the company, valued at approximately $944,772.84. This trade represents a 16.70% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 105,000 shares of company stock worth $1,432,952 over the last ninety days. Corporate insiders own 5.70% of the company’s stock.
About Oric Pharmaceuticals
Oric Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing medicines for cancer. Its research centers on therapies intended to address treatment resistance and improve outcomes for people with tumors that have become difficult to treat.
The company’s drug candidates have included ORIC-114, a targeted therapy designed to inhibit EGFR and HER2 alterations, and ORIC-944, which targets the PRC2 pathway and has been investigated for prostate cancer. These programs are investigational and are not approved medicines.
Founded in 2014, Oric is headquartered in South San Francisco, California.
Read More
- Five stocks we like better than Oric Pharmaceuticals
- Wall Street May Be Making a Big Mistake With monday.com Stock
- Are These 2 Mid-Cap Growth Stocks Worth the Risk?
- Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?
- Cloudflare’s 20% Sell-Off May Have Created an Opening for Investors
Receive News & Ratings for Oric Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oric Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
